SEATTLE--(BUSINESS WIRE)--Seattle Genetics, Inc. (NASDAQ:SGEN), today announced that its management will host a teleconference at 5:30 a.m. Pacific Time (PT) / 8:30 a.m. Eastern Time (ET) on Tuesday, December 15, 2009, to discuss brentuximab vedotin (SGN-35) partnering. A press release with respect to brentuximab vedotin partnering will be issued prior to the teleconference. Brentuximab vedotin is an antibody-drug conjugate (ADC) targeting CD30 that is in clinical trials for the treatment of relapsed and refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL).
